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Abstract
Background: Multiple Sclerosis (MS) is an immune-mediated inflammatory disease of the Central Nervous System
(CNS) which damages the myelin sheath enveloping nerve cells thus causing severe physical disability in patients.
Relapsing Remitting Multiple Sclerosis (RRMS) is one of the most common form of MS in adults and is characterized by
a series of neurologic symptoms, followed by periods of remission. Recently, many treatments were proposed and
studied to contrast the RRMS progression. Among these drugs, daclizumab (commercial name Zinbryta), an antibody
tailored against the Interleukin-2 receptor of T cells, exhibited promising results, but its efficacy was accompanied by
an increased frequency of serious adverse events. Manifested side effects consisted of infections, encephalitis, and liver
damages. Therefore daclizumab has been withdrawn from the market worldwide. Another interesting case of RRMS
regards its progression in pregnant women where a smaller incidence of relapses until the delivery has been observed.
Results: In this paper we propose a new methodology for studying RRMS, which we implemented in GreatSPN, a
state-of-the-art open-source suite for modelling and analyzing complex systems through the Petri Net (PN) formalism.
This methodology exploits: (a) an extended Colored PN formalism to provide a compact graphical description of the
system and to automatically derive a set of ODEs encoding the system dynamics and (b) the Latin Hypercube Sampling
with PRCC index to calibrate ODE parameters for reproducing the real behaviours in healthy and MS subjects.
To show the effectiveness of such methodology a model of RRMS has been constructed and studied. Two different
scenarios of RRMS were thus considered. In the former scenario the effect of the daclizumab administration is
investigated, while in the latter one RRMS was studied in pregnant women.
Conclusions: We propose a new computational methodology to study RRMS disease. Moreover, we show that
model generated and calibrated according to this methodology is able to reproduce the expected behaviours.
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Background
Multiple Sclerosis (MS) is a chronic and potentially highly
disabling disease with considerable social impacts and
economic consequences. In Europe it is the leading cause
of non-traumatic disabilities in young adults, since more
than 700,000 EU people suffer fromMS [1].
Multiple sclerosis is an inflammatory autoimmune dis-
ease in which the patient’s immune system reacts against
itself by damaging CNS nerve cells - i.e. compromising the
ability of the neurons to send electrical signals - result-
ing in a progression of physical handicap until complete
paralysis within 25 years in more than 30% of patients [2].
In literature four courses of MS are identified:
Relapsing-Remitting MS (RRMS), Secondary Progressive
MS (SPMS), Primary Progressive MS (PPMS), and Pro-
gressive Relapsing MS (PRMS). Among them the RRMS
is the most common course since it is diagnosed in about
85% of MS cases. It is characterized by episodes of neuro-
logical dysfunction (i.e. relapses) followed by a complete
or partial recovery (i.e. remissions). Unfortunately, within
25 years RRMS usually changes to SPMS (in about 90% of
cases) increasing the severity of the disease. [1]
Despite the etiology of MS is unknown, researchers
agree that also environmental factors can act as triggers
of MS, leading to the inflammatory process in the Cen-
tral Nervous System (CNS). In particular, viruses may play
a role in MS pathogenesis acting as such environmental
triggers. Some studies linked MS with Epstein Barr Virus
(EBV) infection due to the presence of higher titers of
EBV antibodies in MS patients compared to age-matched
controls [3].
Besides environmental factors, physiological factors
also impact on the outcome of the MS disease. In par-
ticular, pregnancy represents a period of immune toler-
ance for patients that has important consequences on
the relapse rate [4]. Indeed, pregnancy condition seems
to have beneficial effects on women patients which have
been associated with fewer relapses in RRMS. This phe-
nomenon has been related with an increase in a particular
type of immune cells, the Regulatory T lymphocytes cells
(Treg), which confers fetal tolerance and thus shows a
protective effect of pregnancy to patients [5].
In the last two decades the advances in the understand-
ing of the immune pathogenesis of MS and the advent
of Monoclonal Antibodies (mAb) allowed researchers to
define novel treatments against this disease. In particu-
lar mAb are powerful new tools to modify the course
of MS based on a molecular targeted approach. Indeed,
they are potentially able to break the immune cascade of
events that brings to the autoimmune reaction causing
the myelin loss. Therefore, these treatments that include
several mAbs such as Natalizumab, Rituximab, and Alem-
tuzumab, constitute nowadays the most effective first and
second line treatments in the therapy of MS [6–8].
Moreover, when the first and second line treat-
ments provide an inadequate response in patients,
daclizumab (DAC) treatment [9] represented the only
third line treatment to be used as a valid alter-
native. Differently from the other mAbs, DAC is a
humanized monoclonal IgG1 antibody tailored against
InterLeukin-2 Receptor (IL2R), thus able to break the
autoimmune reaction by suppressing the immune cells
expansion.
The basic mechanism of MS is, however, not fully
understood yet and, despite its promising results, in
2018 DAC was withdrawn from the EU marketing autho-
rization process due to the observation of twelve cases
of patients who developed, after the beginning of the
treatment, serious immune-mediated adverse reactions
at the level of the CNS, including encephalitis and
meningoencephalitis. More studies are needed to under-
stand these effects as well as to explain why women
affected by MS seem to improve when they become preg-
nant and during the pregnancy period. To improve our
understanding of these phenomena, in this paper we
extend the RRMS models presented in [10–12] propos-
ing a new computational methodology to analyse the
RRMS behaviour. Hence, we firstly describe how the
Extended Stochastic Symmetric Net (ESSN) formalism
can be efficiently used to derive a graphical and para-
metric description of the system under study. Then, we
show how the system of Ordinary Differential Equations
(ODEs), that can be automatically derived from an ESSN
model, reproduces the disease dynamics and how uncer-
tainty and sensitivity analysis can be used to make
more robust the results provided by the model. Finally
we tested the proposed methodology constructing a
model which allows to represent two different scenar-
ios where the effect of the daclizumab administration
is investigated and the RRMS in pregnant women is
considered.
Methods
Introduction to petri net formalism
In this section we provide an intuitive introduction to the
formalism used to model and analyze our case study. The
Petri Net formalism is firstly introduced, then a specific
type of high-level extension, called Stochastic Symmetric
Net (SSN) [13], is described. After, the technique used to
derive the qualitative properties of systems modelled with
this formalism is discussed showing how these results
can be computed efficiently using a fluid approximation.
Then a new extension of the SSN formalism, called ESSN,
is introduced to deal easily with more complex biologi-
cal laws different by Mass Action one. Finally, in the last
part of this section we describe how the model sensi-
tivity analysis can be carried out using a sampling-based
method.
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Petri net and stochastic symmetric net
Petri Net (PN) [14] and their extensions are well-known
computational and mathematical formalisms which pro-
vide a graphical intuitive and formal description of the
important features of the system under study. They allow
the use of different analysis techniques to derive the qual-
itative and quantitative properties of a system.
PNs are bipartite directed graphs with two types of
nodes, namely places and transitions. Places, correspond
to state variables of the system and are graphically repre-
sented as circles. For instance, in Fig. 1 an example PN
model is presented, where it is described i) the Effector T
cells (Teff ) attack to the myelin sheaths due to the struc-
ture similarity of the viral protein with myelin proteins,
and ii) the Oligodentrocytes cells (ODC) recovery of the
lost myelin when the damage is not irreversible. Indeed,
these events play a central role in RRMS progression,
and more details will be given in Sec. Model description.
Here the Teff and ODC nodes are model places repre-
senting the Effector T cells and the Oligodentrocytes cells,
respectively.
Differently, transitions correspond to the events that can
induce a state change and are graphically represented as
boxes. Referring again to Fig. 1, transitions are TeffDeath,
Remyelinization andTeffKillsODC which simulate the Teff
death, the ODC recovery, and the damages of the Teff over
the ODC cells, respectively.
The arcs connecting places to transitions (and vice-
versa) express the relation between states and event occur-
rences. Places can contain tokens, drawn as black dots.
Fig. 1 Example of SSN. Example of SSN representing the Effector T
cells ( place on the top named as Teff) which damage the
Oligodentrocytes cells (place on the bottom named as ODC), and
their partially recovery of the lost myelin when the damage is not
excessive. This is a sub net of the SSN represented in Fig. 2
The state of a PN, called marking, is defined by the
number of tokens in each place of the model.
The system evolution derives from the firing of enabled
transitions, where a transition is enabled if and only if each
input place contains a number of tokens greater or equal
than a given threshold defined by the cardinality (multi-
plicity) of the corresponding input arc. Thus, the firing of
an enabled transition removes a fixed number of tokens
from its input places and adds a fixed number of tokens
into its output places, according to the cardinality of its
input/output arcs.
Among the PN generalisations proposed in literature,
SSNs [13] extend PNs providing a more compact and
readable representation of the system, thanks to the pos-
sibility of using tokens belonging to different classes and
thus graphically represented in the models as dots of
different colors.
In SSNs each place p has an associated color domain (a
data type) denoted cd(p) and each token in a given place
has an associated value defined by cd(p). Color domains
are defined by the Cartesian product of elementary types
called color classes C = {C1, . . . ,Cn}, so that cd(p) = Ce11 ×
Ce22 × . . .×Cenn where ei is the number of times Ci appears
in cd(p). Color classes are finite and disjoint sets. They can
be ordered (in this case a successor function is defined on
the class, inducing a circular order among the elements in
the class), and can be partitioned into (static) subclasses
(e.g Ci,j is the ith static subclass of the jth color class).
In the example model represented in Fig. 1 the ODC
color domain is defined by one color class, the myelina-
tion levels of ODC cells, named Mye. This is divided into
5 static subclasses (i.e. Lmin, L1, L2, L3 and Lmax) so
that myelination level ranges from an irreversible damage
(Lmin, no myelination) to no damages (Lmax, full myelina-
tion). Similarly, a color domain is associated with transi-
tions and is defined as a set of typed variables, where the
variables are those appearing in the functions labeling the
transition arcs and their types are the color classes. For
instance, the color domain of transition Remyelinization,
representing the recovery of a ODC cell, is Mye and the
variable characterizing its input arc is l ∈ Mye.
An instance of a given transition t is an assignment of
the transition variables to a specific color of proper type.
Hence, we use the notation 〈t, c〉 to denote an instance,
where c is the assignment, also called binding. Moreover,
a guard can be used to define restrictions on the allowed
instances of a transition. A guard is a logical expression
defined on the color domain of the transition, and its
terms, called basic predicates, allow (i) to compare colors
assigned to variables of the same type (x = y, x = y); (ii)
to test whether a color element belongs to a given static
subclass (x ∈ Ci,j); (iii) to compare the static sub-classes of
the colors assigned to two variables (d(x) = d(y), d(x) =
d(y)).
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Themarking of an SSN is defined by the number of col-
ored tokens in each place. For instance, a possible marking
of the placeDAC in Fig. 1, is 500 〈Lmax〉 corresponding to
500 ODC cells with a full myelination.
Each arc connecting a place p to a transition t, namely an
input arc of t, is labeled with an expression defined by the
function I[ p, t] : cd(t) → Bag[ cd(p)], where Bag[A] is the
set of multisets built on set A, and if b ∈ Bag[A]∧a ∈ A,
b[ a] denotes the multiplicity of a in the multiset b. Simi-
larly, each arc connecting a transition t to a place p, namely
an output arc of t, is denoted by the function O[ p, t] :
cd(t) → Bag[ cd(p)]. Thus, the evaluation of I[ p, t] (resp.
O[ p, t]), given a legal binding of t, provides the multiset
of colored tokens that will be withdrawn from (input arc)
or will be added to (output arc) the place connected to
that arc by the firing of such transition instance. More-
over, we denote with •t the set of input places of the
transition t and with t• the set of output places of t, i.e.
•t := {p ∈ P| ∃ c ∈ cd(p) s.t. I[ p, t] (c′)[ c]> 0} and t• :=
{p ∈ P| ∃ c ∈ cd(p) s.t. O[ p, t] (c′)[ c]> 0}. In details, a
transition instance 〈t, c〉 is enabled and can fire in anmark-
ing m, iff: (1) its guard evaluated on c is true; (2) for each
place p we have that I[ p, t] (c) ≤ m(p), where ≤ is the
comparison operator among multisets. We use the nota-
tion E(t,m) to denote the set of all instances of t enabled
inmarkingm. The firing of the enabled transition instance
〈t, c〉 in m produces a new marking m′ such that, for each
place p, we havem′(p) = m(p) + O[ p, t] (c) − I[ p, t] (c).
In the SSNs, the firing time of an enabled transition
instance 〈t, c〉 is sampled from a negative exponential
distribution whose rate is given by the function ω, i.e.
ω(t, c) =
{
ri condi(c) i = 1, . . . , n,
rn+1 otherwise,
where condi are boolean and mutually exclusive expres-
sions comprising standard predicates on the transition
color instance. In this manner, the firing rate ri of a tran-
sition instance can depend only on the static sub-classes
of the objects assigned to the transition parameters and
on the comparison of variables of the same type. Thus,
these stochastic firing delays, sampled from a negative
exponential distribution, allow to automatically derived
the stochastic process, i.e. a Continuous Time Markov
Chain (CTMC), that describes the dynamics of the SSN
model. Specifically, the CTMC states are isomorphic to
SSN markings and the state changes correspond to the
marking changes in the model.
Hereafter we recall the formal definition of SSN.
Definition 1 (Stochastic Symmetric Net). An SSN is a
nine-tuple:
NSSN = 〈P,T , C, I,O, cd,,ω,m0〉
where
• P and T are two disjoint finite non empty sets
(representing places and transitions respectively).
• C = {C1, . . . ,Cn} is the finite set of basic color classes.
• cd : ⊗ni=1
⊗ei
j C
j
i is a function defining the color
domain of each place and transition (where ei ∈ N is
the number of occurrences of the class Ci); for places
it is expressed as Cartesian product of basic color
classes, for transitions it is expressed as a list of
variables with their types. Observe that a place may
contain undistinguished tokens only or a transition
may have no parameters, in this case their domain is
neutral.
• I,O[ p, t] : cd(t) → Bag[ cd(p)] are the pre- and post-
matrices, whose elements are in the form of the arc
functions defined above.
•  is the vector of guards and maps each element of T
into a standard predicate ((t) may be the constant
true, which is also a standard predicate).
• ω(t, c) is the function returning the rate of transition
t assuming the firing of the instance 〈t, c〉.
• m0 : P → Bag[ cd(p)] is the initial marking, mapping
each place p on a multiset on cd(p).
Assuming that all the transitions of the SSN are char-
acterized by a Mass Action law, the intensity (also calles
the transition speed) of 〈t, c〉 in marking m is defined as
follows:
ϕ(m, t, c) = ω(t, c)
∏
〈p,c′〉| p∈•t ∧ c′∈cd(p)
m[ p] [ c′]I[p,t](c)[c′] (1)
where m[ p] [ c′] denotes the marking of place p for
color c′.
In the literature, different techniques are proposed to
solve (or analyse) the CTMC underlying an SSN; in par-
ticular, in case of very complex models, the so-called
deterministic approach [15] can be efficiently exploited.
According to this, in [16] we described how to derive a
deterministic process, represented through a system of
ODEs, which well approximates the stochastic behavior of
an SSN model. In particular for each place p and possible
color tuple c ∈ cd(p) we have the following ODE:
dxp,c(ν)
dν =
∑
〈t′,c′〉∈E(t′,x(ν)) ∧ t′∈T
ϕ(x(ν), t′, c′)(L[ p, t′] (c′)[ c] ) (2)
where xp,c(ν) is the average number of tokens of
color c in the place p at time ν, L[ p, t′] (c′)[ c]=
O[ p, t′] (c′)[ c]−I[ p, t′] (c′)[ c],T is the set of transitions of
the SSN, and E(t, x(ν)) the set of the enabled instances of
t in x(ν), i.e. the vector of the average number of tokens at
time ν for each place and possible color tuple. In this case
Eq. 1 becomes
ϕ(x(ν), t, c) = ω(t, c)
∏
〈pj ,c′〉| p∈•t ∧ c′∈cd(pj)
xpj ,c′(ν)I[pj ,t](c
′)[c]. (3)
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Extended stochastic symmetric net
It is important to highlight that the reactions velocity can
be defined by more complex laws thanMass Action (MA),
for instance Michaelis Menten and Hill kinetics. In [17]
the Extended Stochastic Petri Net (ESPN) formalism was
presented to extend SPN with general functions which
make easier to model reactions with more complex bio-
logical laws. Similarly, in this paper we propose a new
formalism, called Extended Stochastic Symmetric Net
(ESSN), which extends the SSN exploiting the same ideas
discussed in the proposal of the ESPN formalism [17].
In details, the set of transitions T is split in two sub-
setsTma andTg . The former subset contains all transitions
which fire with a rate following a MA law. The latter
includes instead all the transitions whose random firing
times have rates that are defined as general real functions.
Hence, we will refer to the transitions belonging to Tma
as standard transitions and as general transitions those
in Tg . For instance, considering the Fig. 1 again, the gen-
eral transition is graphically represented as black box and
is that simulating the myelin damage, i.e. TeffKillODC. In
details, the function of the general transition is given in
the Additional file 1.
Definition 2 (Extended Stochastic Symmetric Net). An
ESSN is a ten-tuple:
NESSN = 〈P,T , C, I,O, cd,,ω,,m0〉
where
• P, C, I,O, cd,,m0 are defined as in SSN (see
definition 1).
• T is the set of transitions and is defined as
T = Tma ∪ Tg , with Tma ∩ Tg = ∅. Where
Tma = {t∗i }1≤i≤nTma is the set of the nTma transitions
whose speeds follow the MA law, and
Tg = {ti}1≤i≤nTg is the set of the nTg transitions
whose speeds are defined as general functions.
• ω(t, c) is the rate of transition t ∈ Tma assuming the
firing of the instance 〈t, c〉.
•  = {f〈t,c〉}t∈T∧c∈cd(t) is set grouping all the transition
speeds ∀t ∈ T . In detail, with t ∈ Tma then
f〈t,c〉 = ϕ(cdot, t, c), where ϕ is defined in Eq. 1.
Similarly to what discussed in Sec. Petri Net and
Stochastic Symmetric Net, let xp,c(ν) ∈ R+ be the continu-
ous approximation of the number of tokens in place p and
color c so that the vector x(ν) ∈ RnP is the marking of the
ESPN at time ν.
Let define xˆ(ν) = x(ν)|•t as the subset of the marking
x(ν) concerning only the input places to the transition t.
Given 〈t, c〉 at the time ν, with transition t ∈ T = Tma ∪
Tg , the firing of 〈t, c〉 will move tokens in state x〈p,c〉(ν)
with speed F(xˆ(ν), t, c, ν) defined as follows:
F(xˆ(ν), t, c, ν) :=
{
ϕ(xˆ(ν), t, c), t ∈ Tma,
f〈t,c〉(xˆ(ν), ν), t ∈ Tg , f〈t,c〉 ∈ (t, c)
(4)
where ϕ(xˆ(ν), t, c) is defined as in Eq. 3. Observe that
ϕ(xˆ(ν), t, c) and f〈t,c〉(xˆ(ν), ν) can depend only on the
marking of the input places of transition t at time ν.
Finally the ODE characterizing the p and color tuple c ∈
cd(p) is defined as:
dxp,c(ν)
dν =
∑
〈t′,c′〉∈E(t′,x(ν))
F(xˆ(ν), t′, c′, ν)(L[ p, t′] (c′)[ c] )
=
∑
〈t′,c′〉∈E(t′,x(ν))
∧t′∈Tma
ϕ(xˆ(ν), t′, c′)(L[ p, t′] (c′)[ c] )
+
∑
〈t′,c′〉∈E(t′,x(ν))
∧t’∈Tg
f〈t′,c′〉(xˆ(ν), ν)(L[ p, t′] (c′)[ c] ) (5)
where xˆ(ν) = x(ν)|•t′ .
Sensitivity analysis
Sensitivity analysis is broadly used in computational mod-
elling to study which parameters affect mostly the vari-
ability of the outcomes produced by the model. Several
approaches are proposed in the literature to achieve this
task, such as Pearson correlation coefficient (CC) method
(for linear relationships), Partial Rank Correlation Coeffi-
cient (PRCC) method (for non-linear and monotonic rela-
tionships) or Fourier Amplitude Sensitivity Test (FAST)
method (for any non-linear relationships) [18, 19]. In this
work we focus on a sampling-based method which com-
bines Latin Hypercube Sampling (LHS) [20] with PRCC
index. Practically LHS, a well-known stratified sampling
method, is adopted to generate samples of the model
input variables. Then the model is run N times in a
chosen interval: one for each generated input variable
sample combination. Finally PRCC between the gener-
ated input variables and the obtained model outputs are
evaluated on the same chosen interval. In this way PRCC
analysis and corresponding significance tests (i.e signifi-
cant p-value) are used to identify key model parameters
and to select time points which need an additional in-
depth investigation. Specifically, PRCC values close to 1
(-1) identify positive (negative) monotone relationships
between inputs and outputs; while the significance tests
allow to discover those correlations that are important,
despite having relatively small PRCC values.
Model description
In this section we first describe how the healthy immune
system achieves the immunosurveillance. Then we focus
on the pathogenesis correlated to MS, highlighting the
roles of the immune system cells, CNS cells, and EBV
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virus. Finally, we describe the structure of the model
dividing it into seven modules.
Healthy case
The immune system represents the entire compartment of
cells leading the defense of the human body against poten-
tially damaging foreign molecules and pathogens with
a highly specific response to the encountered infectious
agents. This specific response is conducted by a stringent
selection and maturation of the naive T lymphocytes in
the lymphoid organs (e.g. thymus), prior to exit in the
periphery of the body asmature T lymphocytes cells. Con-
sequently to the pathogens entrance, the naive T lympho-
cytes become activated T lymphocytes by Antigens Pre-
senting Cells (APCs) via the T Cell Receptor (TCR). The
activated T lymphocytes produce Interleukin-2 (IL2) an
immunomodulating cytokine released for self-stimulating
in order to duplicate and propagate their actions, via the
binding of IL2 to the receptor IL2R, located on the surface
of the cells. Thanks to this bond, activated T lymphocytes
undergo the clonal expansion process (i.e. lymphocytes
multiplication). During clonal expansion, a portion of the
activated T lymphocytes are destined to become Effec-
tor T lymphocytes cells (Teff ) and others as Memory
T lymphocytes cells (Tmem). Thanks to the presence of
Tmem cells, the responses to subsequent attacks from the
same pathogen are faster and greater than the first one.
Since the response of Teff is reversed when no longer
needed, the Treg - response T lymphocytes - contributes
to suppress the Teff cells activity. (see Additional file 1:
Figure S1). In addiction, IL2 brings to the activation of
another family of immune cells, named Natural Killer
(NK) cells that act as host-rejection of infected cells and,
in same cases, against auto-reactive Teff populations, T
lymphocytes recognizing self-molecules as foreign [21].
Multiple sclerosis
MS is an autoimmune disease in which the immune sys-
tem removes the myelin sheath from neuronal axons
of the CNS preventing the efficient transmission of the
nervous signals. RRMS is the predominant type of MS
in which the disease alternates phases of active neural
inflammation and disease worsening (relapses) to remis-
sion phases in which there is a complete or partial lack
of the symptoms. The occurrences of the relapses peri-
ods range from mild to severe, depending on the course
and history of the disease. The occurrence and severity of
relapses are the only measures to estimate the efficacy of
a drug treatment.
Several studies agree with the idea that the damage
at CNS is probably due to auto-reactive T lymphocytes
which recognize the myelin as foreign. Indeed, during the
relapse phase, the continuous attack of T lymphocytes
leads to a progressive decrease of the quantity of myelin
[22]. It is worth to note that in some cases the Oligoden-
trocytes cells (ODC) are able to partially recover the lost
myelin if the damage is not excessive.
As already pointed out in the previous section, several T
lymphocytes with different roles take part in the general
immunosurveillance (e.g. Teff, Treg, Tmem). An imbal-
ance in the T lymphocytes differentiation can lead to a
strong or long-term response that goes beyond its origi-
nal purpose. In fact, in literature it has been hypothesized
that homeostasis of Treg and Teff cells may be crucial
to prevent autoimmunity. Moreover, a breakdown of the
peripheral tolerancemechanisms of Treg (represented, for
example, by a lower duplication rate of Treg compared to
Teff ) can bring to the selection of self-reactive Teff cells
leading to damage in the CNS [23]. The etiology of MS
remains elusive. Some studies linked MS with signs of
Epstein Barr Virus (EBV) infection [3, 24]. A hypothesis
is that the EBV first infection as well as the reactiva-
tion of the latent infection can cause the activation of
auto-reactive Teff lymphocytes through a process called
molecular mimicry. Molecular mimicry would cause the
activation of Teff lymphocytes that recognize an EBV
virus protein. However, due to the structure similarity
between the viral protein and myelin proteins, these Teff
could also be able to attack myelin sheaths leading to a
neural damage [3].
A very interesting case of study is the development and
progression of MS in pregnant women. The RRMS preg-
nant women have a lower relapse rate until the delivery
[25]. Indeed, during the pregnancy period the number of
Treg cells increase to establish tolerance against fetal anti-
gens. As a consequence, pregnancy represents a moment
of immune tolerance and well-being for the patients.
Relapsing-Remitting multiple sclerosis model
The cell and molecular interactions involved in the
Relapsing-Remitting Multiple Sclerosis(RRMS) are
described by the model showed in Fig. 2. Our model
consists of 10 places and 22 transitions. For sake of clarity,
the white transitions model mass-action functions, while
the black transitions model different kinetics described
in details in the Additional file 1. All the constants and
numerical values associated with the transitions are
reported in the Additional file 1: Tables S1 and S2. This
model is organized in seven modules corresponding to
the biological entities characterizing RRMS: Treg, Teff,
EBV, NK, IL2, ODC, and DAC.
1) Treg module. The Treg cells are characterized by two
places: the Resting_Treg and Treg. The transition From-
TimoREG represents the arrival of new resting Treg cells
from thymus. Its rate is defined in order to keep constant
the number of resting cells. The transition TregActivation
represents the activation of the resting Treg depending
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Fig. 2 The RRMS model. The RRMS PN model is composed by places (graphically represented by circles) corresponding to cells or molecules, and by
transitions (graphically represented by rectangles) corresponding to the interactions among the entities, injections or death of molecules. The RRMS
model is composed by seven modules: Treg, Teff, EBV, NK, IL2, ODC and DAC
on the Teff cell number and EBV concentration, while
TregDeath represents the death of Treg. The transition
TregKillsTeff models the homeostatic regulation operated
by Treg cells against self-reactive Teff cells, and TregDup
models the Treg duplication.
2) Teff module. The second module is characterized by
three places: Resting_Teff , Teff, and EffectorMemory. The
transitions FromTimoEFF, TeffActivation, and TeffDeath
behave similarly to those described in module 1, but they
are referred to the Teff population.
The Teff proliferation takes place in two different
manners called Symmetrical and Asymmetrical processes.
These two possibilities are captured in the model by
assuming that one happens with probability pdupeff and the
other with probability pmemeff = 1−pdupeff . Given a replication
speed named reffdup, the transition TeffDup_Sym generates
two Teff cells with the rate equals to reffdup ∗ pdupeff , for
more details see Additional Material. Otherwise, the tran-
sition TeffDup_Asym takes place with a speed resulting
from the product reffdup ∗ pmemeff replicating one Teff cell into
one T Memory effector cell and one Teff cell. The tran-
sitions TeffKillsEBV and TeffKillsODC encode the killing
effect of Teff cells against EBV and ODC, respectively.
Finally, MemActivationmodels the rapid activation of the
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Effector Memory depending on both the EBV and the
Tmem concentrations.
The transitions TeffKillsEBV and TeffKillsODC encode
the killing effect of Teff cells against EBV and ODC,
respectively. Finally, MemActivation models the rapid
activation of the Effector Memory depending on both the
EBV and the Tmem concentrations.
3) EBV module. The third module describes the EBV
behaviour. Transition EBVinj models the infection. The
TeffKillsEBV transition summarizes all steps from antigen
processing and presentation by EBV infected cells to Teff
cells, to the activation of Teff cells.
4) NK module. In this modules the role of the NK cells
is described. The transition NKentry models the arrival
of new NK cells. The death of NK is then modeled by
transition NKDeath. Transitions NKKillsTeff and NKKill-
sTreg encode the killing of self-reactive Teff and Treg cells
respectively due to NK cells. Finally NKdup models the
proliferation of the NK cells led by the presence of IL2.
5) IL2 module. The fifth module is focused on the IL2
role. IL2 is involved in the Treg, Teff andNK proliferation.
All these types of cells consume IL2 which is produced by
the transition TeffActivation.
6) ODC module. The sixth module encodes the ODC
behaviour. The transition TeffKillsODC models the dam-
age caused by Teff cells on ODC cells. When the myelina-
tion level reaches the lowest value, an irreversible damage
occurs and the remyelinization is nomore possible (i.e. the
transition Remyelinization is permanently disabled by its
guard).
To model this effect, we used the color classMye encod-
ing the myelination levels of ODC.Mye is divided into five
static subclasses ranging from Lmin (no myelination) to
Lmax (full myelination).
7) DAC module. In the last module the daclizumab
behaviour is modeled through the place DAC. The
drug administration is modeled by transition DAC-
inj, while the pharmacokinetic inhibiting the expan-
sion of Treg and Teff decreases the velocity of transi-
tions TregDup,TeffDup_Sym and TeffDup_Asym. Finally,
its degradation is modeled by the transition DACDegra-
dation.
Results
In this section we present the prototype computational
framework developed to study the RRMS. Then, we
describe how our model was calibrated to mimic the real
behaviours in healthy and MS subjects. Finally we discuss
also the results coming from two case studies in which we
investigated the effect of the daclizumab administration
on MS patients and the modification of the MS evolution
due to the occurring of a pregnant condition.
Framework architecture
The prototype framework specifically developed for this
project consists of a few modules which interact with
GreatSPN [26], a software suite for modelling and ana-
lyzing complex systems using the PN formalism and
its extensions. The architecture of this framework is
depicted in Fig. 3. The GreatSPN GUI is used to con-
struct the ESSN model. First the coloured portion of a
model “NetName” (similar to that depicted in Fig. 2)
is drawn on the GUI interface, then the “Unfolding”
module is called to transform the coloured model in
a basic Petri Net representation where all the tokens
are assumed to be indistinguishable and the files “Net-
Name.net” and “NetName.def” are produced. Moreover
the generic firing rate functions characteristic of the
ESSN formalism must be specified in a separate file
called “name.rate”. Then the files “NetName.net” and
“NetName.def” and “NetName.rate” are used by the mod-
ule “PN2ODE” to automatically derive the corresponding
system of ODEs producing a file “NetName.r” with a
format suitable for being processed by the “R” software.
Finally the “R” environment is used for the solution of
the set of ODEs, for carrying out the sensitivity anal-
ysis with respect to model parameters, and for com-
puting interesting results in terms of numerical values
and diagrams. As the whole framework is not yet com-
pletely integrated with GreatSPN, calling the “Unfold-
ing” and “PN2ODE” modules, as well as the interaction
with the “R” software, must be done using command-line
directives. GreatSPN extended with this prototype frame-
work can be downloaded at https://github.com/greatspn.
Instead, all the R files and the GreatSPN files of the
net are freely available at https://github.com/qBioTurin/
ESSNandRRMS/tree/master/DeterministicModel.
Model calibration for healthy andmS individuals
The model calibration was addressed to select the input
values (transition parameters, and the concentrations of
EBV and DAC) leading outputs of the model towards the
values obtained from observing the behaviour of the spe-
cific quantities both in healthy and MS affected subjects.
The calibration is performed using the LHS with PRCC
index to identify which parameters have more impact
on the model outcomes. Then, the identified parame-
ters were thoroughly investigated in the healthy and MS
individuals.
From our model (without the DAC module, Fig. 2)
a system of 13 ODEs with nine input parameters is
derived. The values of these nine parameters were sam-
pled by means of LHS method. Hence, 5000 parameter
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Fig. 3 Framework structure. Outline of the prototype framework combining GreatSPN suite with R. The components are shown by rectangles,
component invocations by solid arrows, models/data exchanges by dashed arrows
combinations were generated using a uniform distribution
whose ranges are showed in the second column of the
Additional file 1: Table S1.
For all the simulations, we assumed as initial marking
the following parameters consistent with a space of 1mm3
of blood and 4mm3 of neural tissue: 500 ODC with level
Lmax of neuronal myelinization, 1687 resting Teff cells, 63
resting Treg cells, 375 NK cells and 1000 IL2 molecules,
and zero cells in the other places (see Additional file 1:
Table S3).
Moreover, we defined the disease occurrence when the
Lmin level of neuronal myelinization is reached for each
ODC cell, representing an irreversible damage. Then, five
virus injections are simulated at regular times (every two
months), introducing into the system 1000 EBV copies
per injection. Finally, model solutions were calculated
for each parameter combination over one year interval,
[ 0, 365] days.
Analyzing the 5000 trajectories generated, three scenar-
ios have been identified: (i) the occurrence of the MS,
represented by a huge number of dead ODC cells; (ii) the
complete remission of the MS disease, characterized by a
low number of dead ODC cells and with a complete elim-
ination of the EBV virus; (iii) the partial remission of the
MS disease specified by a partial elimination of the EBV
virus. The Additional file 1: Figure S2 reports the EBV
and ODC dynamics generated considering different set of
parameters.
On these trajectories the PRCC analysis was applied
to identify key model parameters affecting the system
behaviour. The PRCCs values are calculated for each
parameter over the entire time period. Figure 4 shows the
PRCC values for all the model parameters over the time
interval considered.
The rates associated with transitions TeffKillODC,
TregKillTeff,TeffKillEBV and Recovery result to be the cru-
cial parameters affecting the ODC behaviour. Figure 5
reports a scatter plot in which each point corresponds to
a generated trajectory, its color represents the percent-
age of irreversible ODC damaged at the final time point
(i.e. a grey color corresponds to a lowest percentage of
damaged ODC and a red color to highest one). The sim-
ulations are performed changing the rates of TeffKillEBV
(in the x-axis), the TregfKillTeff (in the y-axis) and Tef-
fKillODC (in the z-axis). A few number of irreversible
damaged ODC are obtained increasing the TregfKillTeff
rate and the decreasing the others two rates.
The key parameters identified were deeply studied
exploiting the LHS method computing 500 new combina-
tions varying only TeffKillEBV, TregfKillTeff and TeffKil-
lODC. We defined two sets of parameters (see Additional
file 1: Table S4), one for the MS patients and one for the
healthy subjects, see Fig. 6.
The MS patients are modelled by a set of parameters
which maximizes the ODC damage maintaining the Treg
and Teff cell numbers consistent with those measured in
the reality, see red trajectories in Fig. 6a and b panels.
For the healthy cases, we selected the trajectory pro-
viding a Teff-Treg regulatory balance able to control the
spread of the EBV virus and to minimize the irreversible
damage to ODC cells, even if the amount of EBV in each
injection is substantially increased, see blue trajectories in
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Fig. 4 Sensitivity analysis. PRCCs over the whole time interval for each model parameter is reported. Yellow area represents the zone of
non-significant PRCC values
Fig. 6, panels a and b. In particular, we performed 500 sim-
ulations varying the amount of EBV injected in a range of
[ 1000 − 5000 particles/mm3]. From Fig. 7 it is possible
to observe that, even for large quantities of EBV injected,
the percentage of irreversibly damagedODCs reaches 17%
(Fig. 7a). This value is very small if compared with respect
to the 77% of irreversibly damaged ODCs in the case of
the disease occurrence. Moreover, independently of the
quantity of EBV injected, Teff are able to eliminate EBV
completely (Fig. 7d), and the abundance of EBV does not
drastically affect the number of effectors or regulators in
the system (Fig. 7b,c).
DAC therapy
To investigate the effect of the DAC therapy in our RRMS
model calibrated for MS patients, we simulated the DAC
administration at the 53rd day after the first EBV injec-
tion. Our results are reported considering two important
aspects in the modulation of a therapy: the drug dose and
the drug degradation time. The quantity of DAC adminis-
trated per injection and the DAC cells deterioration were
studied by means of LHS method. The values of these
two parameters are then sampled according to two uni-
form distributions whose ranges are reported into the
Additional file 1: Table S1.
From the LHS analysis we clearly observed that the
drug degradation time has a greater impact on the elim-
ination of EBV virus than the amount of DAC adminis-
tered, see the number of ODC irreversibly damaged in
Additional file 1: Figure S3. Therefore, we decided to focus
our attention on the DACDegradation parameter vari-
ation. Knowing that the half-life of DAC was detected
around 22 days, we considered that a complete degrada-
tion of DAC ranges between 30 and 90 days [27]. The
results of the simulations are reported in Fig. 8a in which
it is possible to appreciate that a greater DAC permanence
has the effect of reducing the number of irreversibly dam-
aged ODC cells with respect to the case in which no ther-
apy was considered (red line). Moreover, it is interesting
to note that the RRMS model with DAC injections high-
lights a decrease of the long term ability of the immune
system to eliminate EBV Fig. 8b. Finally, in Additional
file 1: Figure S4 is reported the trend of the NK cells that
increase with respect to the DAC degradation rate.
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Fig. 5 Parameters scatter plot. 3D scatter plot of the ODC irreversible damaged at the fixed time 365 versus theTeffKillODC, TregKillTeff, TeffKillEBV
parameters variation
Pregnancy
In this subsection we investigate the RRMS in pregnant
women. As already pointed out before, pregnancy was
associated with fewer relapses in RRMS and reduced
activity of disease in autoimmune encephalomyelitis
(EAE). Beneficial effects of pregnancy are thought to be
related to pregnancy-associated changes in the maternal
immune system. One of the observations is that Treg cells
increase in number establishing the fetal tolerance and
conferring a temporary protection to women with RRMS
[28, 29].
According to the literature, we modelled the pregnancy
condition changing the proportion between the activate
Treg cells and the activate Teff cells decreasing the Teff
activation rate and increasing the Treg activation rate pro-
portionally to the pregnancy phase [29]. Three pregnancy
phases, corresponding to the three trimesters, have been
simulated.When a new trimester begins, we increased the
ratio of TregActivation rate to TeffActivation rate; while at
delivery time both rates return to their initial values.
Thus we simulated 100 different scenarios with a
increasing variation of parameters, obtaining different
levels of protection from ODC damage. As expected, the
model behaviour shows a substantial reduction of the
ODCs damage (see Fig. 9).
Regarding the immune system cells, we observed that
Treg cells increase during pregnancy and then suffer a
sharp decline at the time of delivery. The same effect,
but in the opposite direction is showed on Teff cells. It
is interesting to note that a rebound of Teff is reported
in the week following pregnancy, see Additional file 1:
Figures S5.
Discussion
Because of nowadays the computational modelling is
widely recognized to succeed in helping scientists in
Pernice et al. BMC Bioinformatics 2019, 20(Suppl 6):623 Page 12 of 17
Fig. 6 Parameters choice. A set of the 500 trajectories generated by LHS of the EBV virus (a) and the ODC cells with an irreversible damage (b) over
the whole time interval varying the TeffKillODC, TregKillTeff, and TeffKillEBV transition parameters
the study of the complex mechanisms of different dis-
eases, in this paper we presented a new computational
methodology and an associated model to better eluci-
date the dynamics behind the RRMS. Indeed, RRMS
represents a very challenging case study, due to the com-
plexity of the disease which involves many different bio-
logical agents, ranging from molecular to environmental
factors.
We exploited the descriptive power of Extended
Stochastic Symmetric Nets to provide a graphical repre-
sentation of the complex biological system in a compact
and parametric way. Moreover, we used LHSmethod with
PRCC index to calibrate the model parameters. Hence,
we showed the ability of the model to reproduce the typ-
ical oscillatory behavior relating to the onset of RRMS by
supposing a breakdown of the cross-balance regulation
mechanisms at the peripheral level. Moreover, the sim-
ulation of DAC injections in the RRMS model can help
scientists to define the mechanisms of actions of this drug
and to theorize the possible causes of its observed side-
effect on the patients. Instead, the experiments simulating
RRMS in pregnant women can contribute to define the
mechanisms at the basis of the variation of the Treg and
Teff cells.
A challenging issue in the definition of the RRMSmodel
is the calibration of the transition parameters and EBV
and DAC concentrations. The LHS with PRCC index
identified TeffKillODC, TregKillTeff, TeffKillEBV as the
most critical parameters to the model outcomes. This
result agrees with our expectation since these parame-
ters play a central role in the disease progression. In the
analysis of the EBV behaviour in a healthy subject, it is
interesting to note the effect of immune memory which
increases the number of activated Teff cells from the time
of second injection(see Additional file 1: Figure S6). In
particular, thanks to the faster activation of the Tmem
cells with respect to the Teff cells, from the second EBV
injection it is possible to observe a more rapid virus anni-
hilation. Indeed, Tmem cells have a faster activation (i.e.
since they already have the memory of a previous contact
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Fig. 7 Effect of EBV quantities. Different injections of EBV (d) are considered to check if the Teff-Treg (c-b) regulatory loop is able to control the virus
spreading minimizing the irreversible damages to the ODC cells (a)
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Fig. 8 Varying the DAC degradation rate. ODC and EBV trajectories colored depending on DAC degradation rate (expressed in months). The red line
represents the starting sample without drug administration
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Fig. 9 Pregnant woman case: ODC. The ODCs irreversibly damaged considering the pregnant woman case of study. 100 trajectories colored
depending on different variations of the TregActivation and TeffActivation parameters. The red line represents the starting sample without pregnancy.
Furthermore each trimester another variation is applied to these parameters in order to represent the increasing of the maternal immune system
with the EBV) than Teff cells, leading to a more rapid virus
annihilation during the relapses.
In the first set of our experiments we inspected the
effect of the DAC therapy in our model calibrated for
reproducing the behaviors of RRMS patients. A greater
amount of latent EBV is present in the systemwith respect
to the case in which no therapy was considered.
In the DAC therapy module there are two parameters
form whom depend the elimination of EBV virus: the
DAC degradation time and the DAC concentration. Using
the parameter sensitivity analysis, we identified the drug
degradation time as the crucial parameter, while the DAC
concentration has ho effect on the EBV treatment. Indeed,
this slight effect of the DAC concentration in the treat-
ment of MS patients was recently described by Gold and
co-workers [30]. In this paper the authors described a clin-
ical trial involving 76 centers in which the MS patients
have been treated by subcutaneous injections of DAC
HYP 150 mg or 300 mg, or placebo, every 4 weeks for 52
weeks. The annualised relapse rate was lower for patients
given DAC HYP (150 mg or 300 mg) than for those that
received the placebo, However, no significance difference
in terms of relapse between the different DAC doses was
reported. Finally, the DAC analysis revealed the secondary
effects of the DAC immunosuppressive therapy that can
actually increase susceptibility to secondary infections.
The second set of experiments were devoted to study
the effect of RRMS in pregnant patients. The mecha-
nisms at the basis of a partial MS remission during the
pregnancy are not fully understood yet, leading this case
particularly interesting. During pregnancy, the maternal
immunotolerance to the fetus induced Treg prolifera-
tion and reduced the relapse rate, therefore our model
predicts a reduction of ODC damage. Our results are
in line with what comes to us from biological knowl-
edge and clinical observations since the resetting of the
immune system is what significantly influences the course
of the disease during pregnancy and also has been related
with clinical manifestation of increased relapses associ-
ated with the post-partum period. From our results it is
possible to appreciate the difference between the ODC
cells irreversibly damages in the case of MS no pregnant
patients and MS pregnant patients (specially in the case
of max variation of the Treg-Teff balance). This difference
increases from the first trimester to the time of delivery
then returns to become not significant.
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At the best of our knowledge, this is the first paper in
which the colored Petri Nets and the sensitivity analysis
are systematically used to study RRMS.
Conclusions
In this paper we provide a promising application of a
computational framework based on Colured Petri Nets
and sensitivity analysis to perform in silico experiments
helping to improve the understanding of the RRMS dis-
ease, possibly giving some indications that may ameliorate
the clinical management. The results of the simulations
give us the opportunity to identify the key parameters
involving in the modulation of the effect of the DAC ther-
apy. Moreover, the simulation in the pregnancy in MS
patients mimics the resetting of the immune system. As
future works we will expand the model including differ-
ent cell populations of the immune system for a better
integration between adaptive and innate immunity. More-
over, we plan to insert new color classes in the model to
encode the spatial coordinates of all entities in a cubic tis-
sue portion. In the context of precision medicine, we may
exploit the model to predict the patient-specific outcome
when the DAC therapy is administered. This will require
an initial model calibration with patient-specific clinical
data. Indeed, our model contains a set of crucial input
parameters regarding the concentration of immune cells
in different modules (e.g. Teff module, NK module, and
ODC module) that can be retrieved from clinical data of
each patient. Then, these values can be used to personal-
ize the model in order to obtain the DAC administration
schedule tuned with respect to the patient characteristics.
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